• Je něco špatně v tomto záznamu ?

A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide

B. Gamberi, C. Berthou, M. Hernandez, G. Semenzato, E. Tholouli, R. Hájek, J. Caers, M. Dimopoulos, MC. Minnema, B. Andreasson, J. Parreira, G. Crotty, K. Remes, E. Kueenburg, B. Rosettani, A. Di Micco, S. Peters, P. Bacon, IW. Blau

. 2020 ; 20 (10) : e629-e644. [pub] 20200513

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026505

INTRODUCTION: Lenalidomide plus dexamethasone is effective and well tolerated in relapsed/refractory multiple myeloma (RRMM). In this observational, noninterventional European post-authorization safety study, the safety profile of lenalidomide plus dexamethasone was investigated and compared with that of other agents in the treatment of RRMM in a real-world setting. PATIENTS AND METHODS: Patients had received ≥ 1 prior antimyeloma therapy; prior lenalidomide was excluded. Treatment was per investigator's routine practice. Adverse events were analyzed by incidence rates per 100 person-years to account for differences in observation length and treatment duration. RESULTS: In total, 2150 patients initiated lenalidomide, and 1479 initiated any other antimyeloma therapy, predominately bortezomib (80.3%), which was primarily administered intravenously (74.3%). The incidence rate of neuropathy was lower with lenalidomide (10.5) than with bortezomib (78.9) or thalidomide (38.7). Lenalidomide also had a lower incidence rate of infections (68.7) versus bortezomib (95.9) and thalidomide (76.0). Conversely, the incidence rate of neutropenia was higher with lenalidomide (38.0) than with bortezomib (18.2) or thalidomide (25.7). The incidence rates of thrombocytopenia were 24.4, 40.4, and 14.4 with lenalidomide, bortezomib, and thalidomide, respectively. CONCLUSION: No new safety signals for lenalidomide were identified in this study, which is the largest prospective real-world European study of lenalidomide in patients with RRMM to date. These results confirm that the safety profile of lenalidomide plus dexamethasone in RRMM in a real-world setting is comparable to that reported in clinical trials.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026505
003      
CZ-PrNML
005      
20211026132840.0
007      
ta
008      
211013s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clml.2020.05.006 $2 doi
035    __
$a (PubMed)32605897
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gamberi, Barbara $u Department of Hematology, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy. Electronic address: gamberi.barbara@asmn.re.it
245    12
$a A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide / $c B. Gamberi, C. Berthou, M. Hernandez, G. Semenzato, E. Tholouli, R. Hájek, J. Caers, M. Dimopoulos, MC. Minnema, B. Andreasson, J. Parreira, G. Crotty, K. Remes, E. Kueenburg, B. Rosettani, A. Di Micco, S. Peters, P. Bacon, IW. Blau
520    9_
$a INTRODUCTION: Lenalidomide plus dexamethasone is effective and well tolerated in relapsed/refractory multiple myeloma (RRMM). In this observational, noninterventional European post-authorization safety study, the safety profile of lenalidomide plus dexamethasone was investigated and compared with that of other agents in the treatment of RRMM in a real-world setting. PATIENTS AND METHODS: Patients had received ≥ 1 prior antimyeloma therapy; prior lenalidomide was excluded. Treatment was per investigator's routine practice. Adverse events were analyzed by incidence rates per 100 person-years to account for differences in observation length and treatment duration. RESULTS: In total, 2150 patients initiated lenalidomide, and 1479 initiated any other antimyeloma therapy, predominately bortezomib (80.3%), which was primarily administered intravenously (74.3%). The incidence rate of neuropathy was lower with lenalidomide (10.5) than with bortezomib (78.9) or thalidomide (38.7). Lenalidomide also had a lower incidence rate of infections (68.7) versus bortezomib (95.9) and thalidomide (76.0). Conversely, the incidence rate of neutropenia was higher with lenalidomide (38.0) than with bortezomib (18.2) or thalidomide (25.7). The incidence rates of thrombocytopenia were 24.4, 40.4, and 14.4 with lenalidomide, bortezomib, and thalidomide, respectively. CONCLUSION: No new safety signals for lenalidomide were identified in this study, which is the largest prospective real-world European study of lenalidomide in patients with RRMM to date. These results confirm that the safety profile of lenalidomide plus dexamethasone in RRMM in a real-world setting is comparable to that reported in clinical trials.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lenalidomid $x farmakologie $x terapeutické užití $7 D000077269
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x farmakoterapie $7 D009101
650    _2
$a prospektivní studie $7 D011446
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Berthou, Christian $u Centre Hospitalier Régional Universitaire, Hôpital Auguste Morvan, Brest, France
700    1_
$a Hernandez, Miguel $u Hemotherapy Service, Hospital Universitario de Canarias, Tenerife, Spain
700    1_
$a Semenzato, Gianpietro $u Department of Medicine, Azienda Ospedale Università di Padova, Padova, Italy
700    1_
$a Tholouli, Eleni $u Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom
700    1_
$a Hájek, Roman $u Department of Clinic Subjects, University Hospital Ostrava and Faculty of Medicine Ostrava, Ostrava, Czech Republic
700    1_
$a Caers, Jo $u Department of Hematology, Centre Hospitalier Universitaire de Liège, Liège, Belgium
700    1_
$a Dimopoulos, Meletios $u National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
700    1_
$a Minnema, Monique C $u Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands
700    1_
$a Andreasson, Bjorn $u Uddevalla Hospital, NU Hospital Group, Uddavella, Sweden
700    1_
$a Parreira, Joana $u Instituto de Histologia e Biologia do Desenvolvimento, Faculdade de Medicina, Universidade de Lisboa and Instiuto Português de Oncologia, Francisco Gentil, Lisboa, Portugal
700    1_
$a Crotty, Gerard $u Department of Haematology, Midland Regional Hospital, Tullamore, Ireland
700    1_
$a Remes, Kari $u Department of Internal Medicine, Turku University Hospital, Turku, Finland
700    1_
$a Kueenburg, Elisabeth $u Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
700    1_
$a Rosettani, Barbara $u Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
700    1_
$a Di Micco, Antonia $u Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
700    1_
$a Peters, Sarah $u Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
700    1_
$a Bacon, Pamela $u Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
700    1_
$a Blau, Igor Wolfgang $u Department of Internal Medicine III, Charité Campus Benjamin Franklin, Berlin, Germany
773    0_
$w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 20, č. 10 (2020), s. e629-e644
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32605897 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132846 $b ABA008
999    __
$a ok $b bmc $g 1715278 $s 1147012
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 20 $c 10 $d e629-e644 $e 20200513 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace